Jazz Pharmaceuticals JAZZ Investments - Amortized Cost Basis
Investments - Amortized Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's investments - amortized cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Jazz Pharmaceuticals's investments - amortized cost basis?
- Jazz Pharmaceuticals (JAZZ) reported investments - amortized cost basis of $4.3M in Q1 2026.
- How has Jazz Pharmaceuticals's investments - amortized cost basis changed year-over-year?
- Jazz Pharmaceuticals's investments - amortized cost basis decreased by 0.0% year-over-year, from $4.3M to $4.3M.
- What is the long-term trend for Jazz Pharmaceuticals's investments - amortized cost basis?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's investments - amortized cost basis has grown at a -71.1% compound annual growth rate (CAGR), from $2.13B to $4.3M.